Member Info for alfista

My thoughts are similar. I think this is the precursor to the next RNS, which will be a significant fundraising. The mood managers on the other channel will kick off shortly, but consider this:- It is feasible that By Health would seek to establish a holding in Provexis as a way of settling the cash needs long term. On that basis, it is also feasible that new funds could be at a premium. The news reiterates that By Health have a target market of a mere 230 million people, however, if that were to be extrapolated to a worldwide figure, then the target could well exceed 1 billion. Those are just facts. However, further research expenditure at this stage may well weigh on sentiment. IMHO

Well, we don't know what they offered, so I don't see how you can make that judgement. At the time, only syrup available, taste was an obvious issue for use in drinks. Since then, the strong trend has been in dietary supplements, which is not the CC field at all. My guess is that the offer was for the IP, at an insulting price, in order to keep it off the market. Not for me ta. DSM have given us star billing at many trade events. So it takes longer, and involves companies we've not heard of. Luckily the mega brands can't control the whole global market, only the unhealthy part of it.

The frequency of publication of Dr Niamh's work has stepped up considerably this year. Safe alternatives resonate with consumers these days. Fonters, we know there'll be a fundraising. Whether or not it will be the last is debatable, depending on plans to expand promotion of Fruitflow + Omega3. As revenues from DSM have risen consistently over several accounting periods, the covering of standard overheads may be imminent. Establishing recurring revenues from direct sales is still very much at base camp. What is the correct mcap for the IP holder of a safe, natural blood flow enhancer being marketed worldwide? I doubt that either of our views will make much difference, my suspicion is that the collaboration with Chinese health supplement retail giant By Health will be the dominant driver over the short to medium term.

Bantam did signal his intentions. Shame if it was him leaving, but if he's realised a fat gain elsewhere, I can follow his logic. The other recurring topic on t'other channel, I just had a look at the monthly gap on my repeat orders. Sometimes they are divisible by three, but most times they're not. Make of that what you will.

You'd have to beat me to them ! :-) Strange how, when it gets to mid 40's, it get's a nosebleed. Something has to break that trend, and I believe it should be more frequent publicity of achievements, or at least a researcher with the ability to seek out and collate newsworthy items. I don't have the time or ability to do that, but I see it on many other share chat boards. I wouldn't like ramping posts, but, in order to progress, some more folks have to become aware, hopefully folks with a long term view based on, as you say, a sound and progressive dividend policy.

Sorry but that all comes across as a bit of industry b**ching. The target set is just one factor, surely the performance of the company in growing and widening its professional offer will be the factor which will help it achieve growth of sp. 6.4p eps merits and sp way up from here IMHO. Took advantage earlier and spent up my remaining ISA allowance.

Has it? From odd snippets I've read about conversations with SM, the conditions that CC would have sought were not agreeable. Just business. So they went the DSM route, much longer, but with full commitment to world roll out.

Ta. Info only goes back to 09 on here. Clearly Moggsies didn't run it for long, like so many start up brands.

Never saw that piece of information, got a link? Sirco back then tasted pretty bad. Order 11769, consistently growing gap, supported by editorial content that costs little or nothing. A massive spend at this stage wouldn't get my vote, rather a gradual increase matching sales growth.

Not meant to be, but I have seen that dodgy character trying his best to mood manage over a long period. OK, you say 10 years, whereas, if as you say you are under water, then you must have bought in late 2009, which is seven and a half years. Which is a long time I agree. Was it a transformative time as stated at the time? Yes, Fruitflow syrup only was made in their lab at that time, now it is made industrially, in powder form too. It was available only in Sirco, in H&B and Waitrose in some stores in UK, now it is available in a multitude of formats, across most of the world. It was sold only by Provexis, to MM, now it is sold to lots of different suppliers, through DSM, worldwide. Did transformative mean that the sp would boom from the price folks paid, including the whining mob (I don't include you in that) ? No, of course not, we all paid the price we paid, many didn't take in to account the market cap at the time, just read the wild claims written on here and other boards. Some, like the devious character on the other site, and his Bessie, bought in a grand gesture, at the time being the worst of the rampers in suggesting a £100 million market cap was feasible for a product made in a cottage industry scale at the time. Others have bought and sold, fair enough, all can do that, and some have added strategically over a long period of time, watching the actual progress and making their moves accordingly. Last year at this time, the moody posts were about the same, affected by funding issues, making purchases at that time very attractive. Haven't added since, but may do at this level. Didn't sell on the By Health news, should have. We need directors, legal requirement. Provexis's task was just financial reporting and IP maintenance, both done professionally . Now, there is the marketing of Fruitflow + Omega3 as an added factor. Scope for further part time roles if we are being aggressive about it, but, I hope, not yet. The contribution of Dr Niamh is immense IMHO, a whole raft of well presented articles published by mainstream and specialist media, explaining the science and beginning the monumental task of impressing folks that good blood flow is as vital as other aspects of heart health. Establishing that thought in the minds of the masses was never going to be as easy as so many numbskulls have claimed. It is ongoing, and the results of it still very unclear. Just the thoughts of one individual, I really don't need the troll posts in response to every post, but I'm sure they'll be there.

Looks to me like Colbs is buying the manipulatory posts of the board policeman. Far more complex to arrive at a revenue figure, since by the evidence it isn't anything like a simple fraction of sales. So I won't, never have, never will. The point being, I suppose, those who long for a global brand have completely misinterpreted every single product launch since the first one Despite being told what the trajectory is, they still want to stamp their feet and demand that it is the way THEY want it. Delusional. Take By Health as a recent example. What sector do they operate in? Fairly large clue there.

Sorry I see that analysis as utterly idiotic. The strategy was set out from the start. The only way to gain market share is by investing in brand strength in as wide a market area as possible. That takes money. Good job they have the backing of some serious II investors who know how a company is built.

Earnings per share of 6.4p, currently 44p to buy ??? Errm, hello? Market, wake up please.

They don't receive commission. This is getting to dunce levels now.

They then raised funds

£411k

Not at all fonters, comparing Fruitflow to garlic is just so uninformed. As for it disappearing, when a major move in to the colossal China market is due, backed by the regulatory expertise of By Health? I should coco.

If you had studied even the basics of the health claim behind Fruitflow, you'd realise just what a clot you make yourself look. Which I quite enjoy.

Some would think that, and some would think otherwise. But the revenue stream continues to increase, when the contribution to start up is covered for each product, then the share of profit will increase. I don't know who put £250k there, the last published accounts disagree with that. But the investment, over all the years, to establish a proper science based claim for Fruitflow, will continue to grow for years to come as further education and medical advocacy reinforces consumer awareness. Each to their own. If you think it will go right back down, fine, wait for that. Not a problem to me, why should it be?

I'd rather soo the Fruitflow Plus product offering expanded in the market place, as blood flow is the neglected elemnt of good heart health so far. Companies come to markets for funds, simple. If the funding is through PrimaryBid, I may be a buyer. As for dilution, well, if the end result is greater sales of Fruitflow, worldwide, I see that as OK